Last month, Alphabet’s artificial intelligence subsidiary, DeepMind, stunned the world of science by presenting something truly spectacular: a snapshot of nearly every existing protein on Earth — 200 million of them.
This machine-learning feat could speed the creation of new drugs. It has already upended my own skepticism about the role artificial intelligence can play in the pharmaceutical industry.
AlphaFold, DeepMind’s protein structure program, is impressive because it reveals so much fundamental information about living organisms.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.